Evidence map›Paper›PMID 42040558›Full record

ArticleFrontiers in medicine2026

Interstitial lung disease constitutes a significant treatment burden in patients with rheumatoid arthritis.

Toshiyuki Aramaki, Kanako Kojima, Toru Michituji, Ayuko Takatani, Kaoru Terada, Katsumi Eguchi, Yukitaka Ueki, Naoki Iwamoto, Atsushi Kawakami

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Toshiyuki AramakiRheumatic Disease Centre, Sasebo Chuo Hospital, Sasebo, Japan.
Kanako KojimaRheumatic Disease Centre, Sasebo Chuo Hospital, Sasebo, Japan.
Toru MichitujiDivision of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Ayuko TakataniDivision of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kaoru TeradaRheumatic Disease Centre, Sasebo Chuo Hospital, Sasebo, Japan.
Katsumi EguchiRheumatic Disease Centre, Sasebo Chuo Hospital, Sasebo, Japan.
Yukitaka UekiRheumatic Disease Centre, Sasebo Chuo Hospital, Sasebo, Japan.
Naoki IwamotoDivision of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Atsushi KawakamiDivision of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study investigated the impact of interstitial lung disease (ILD), a prevalent complication of rheumatoid arthritis (RA), on the achievement of treatment goals in clinical practice under the treat-to-target (T2T) strategy. Methods: This retrospective observational study included patients with newly diagnosed RA who underwent chest computed tomography (CT) within 1 year of RA onset between 2016 and 2022. The presence of ILD was assessed using chest CT imaging. Treatment goals were evaluated at 6, 12, and 24 months after treatment started. The goals were low disease activity (CDAI < 10), low inflammation (CRP < 0.5 mg/dL), and glucocorticoid (GC)-free status. Then, univariate and multivariate analyses were performed to identify factors impacting goal achievement. Results and discussion: Of the 254 patients, 57 (22.4%) had RA-ILD. Patients with ILD were older, had higher Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) positivity, used GCs more frequently, and had lower methotrexate usage. At all-time points, patients with ILD were significantly less likely to achieve treatment goals than those without ILD (21.2% vs. 37.8% at 6 months,

Indexed as

clinical disease activity indexglucocorticoidRA associated interstitial lung diseaseRA-ILDrheumatoid arthritistreatment to target

Identifiers

PMID42040558
PMCPMC13102581

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.